#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1 .
1-1	0-1	1	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Introduction
2-1	4-16	Introduction	abstract	new	_	_

#Text=The development of flow processes has gained tremendous interest in recent years in organic chemistry due to numerous advantages of such types of processes over classic batch approaches .
3-1	17-20	The	abstract[3]	new[3]	coref	4-27[20_3]
3-2	21-32	development	abstract[3]	new[3]	_	_
3-3	33-35	of	abstract[3]	new[3]	_	_
3-4	36-40	flow	abstract[3]|abstract|abstract[5]	new[3]|new|new[5]	coref|coref|coref|coref	3-24[0_5]|4-30|3-24[0_5]|4-30
3-5	41-50	processes	abstract[3]|abstract[5]	new[3]|new[5]	_	_
3-6	51-54	has	_	_	_	_
3-7	55-61	gained	_	_	_	_
3-8	62-72	tremendous	organization[6]	new[6]	coref	7-5[47_6]
3-9	73-81	interest	organization[6]	new[6]	_	_
3-10	82-84	in	organization[6]	new[6]	_	_
3-11	85-91	recent	organization[6]|time[7]	new[6]|new[7]	_	_
3-12	92-97	years	organization[6]|time[7]	new[6]|new[7]	_	_
3-13	98-100	in	organization[6]|time[7]	new[6]|new[7]	_	_
3-14	101-108	organic	organization[6]|time[7]|abstract[8]	new[6]|new[7]|new[8]	_	_
3-15	109-118	chemistry	organization[6]|time[7]|abstract[8]	new[6]|new[7]|new[8]	_	_
3-16	119-122	due	_	_	_	_
3-17	123-125	to	_	_	_	_
3-18	126-134	numerous	abstract[9]	new[9]	coref	4-7[16_9]
3-19	135-145	advantages	abstract[9]	new[9]	_	_
3-20	146-148	of	abstract[9]	new[9]	_	_
3-21	149-153	such	abstract[9]|place[10]	new[9]|new[10]	_	_
3-22	154-159	types	abstract[9]|place[10]	new[9]|new[10]	_	_
3-23	160-162	of	abstract[9]|place[10]	new[9]|new[10]	_	_
3-24	163-172	processes	abstract[9]|place[10]|abstract	new[9]|new[10]|giv	coref	4-30[22_0]
3-25	173-177	over	abstract[9]|place[10]	new[9]|new[10]	_	_
3-26	178-185	classic	abstract[9]|place[10]|abstract[13]	new[9]|new[10]|new[13]	_	_
3-27	186-191	batch	abstract[9]|place[10]|quantity|abstract[13]	new[9]|new[10]|new|new[13]	coref	7-40
3-28	192-202	approaches	abstract[9]|place[10]|abstract[13]	new[9]|new[10]|new[13]	_	_
3-29	203-204	.	_	_	_	_

#Text=In addition to higher efficiency and safety advantages , the ability to ensure constant product quality has turned out to be a major driving force for the development of flow processes .
4-1	205-207	In	_	_	_	_
4-2	208-216	addition	_	_	_	_
4-3	217-219	to	_	_	_	_
4-4	220-226	higher	abstract[14]	new[14]	_	_
4-5	227-237	efficiency	abstract[14]	new[14]	_	_
4-6	238-241	and	_	_	_	_
4-7	242-248	safety	abstract|abstract[16]	new|giv[16]	_	_
4-8	249-259	advantages	abstract[16]	giv[16]	_	_
4-9	260-261	,	_	_	_	_
4-10	262-265	the	abstract[17]	new[17]	_	_
4-11	266-273	ability	abstract[17]	new[17]	_	_
4-12	274-276	to	_	_	_	_
4-13	277-283	ensure	_	_	_	_
4-14	284-292	constant	abstract[18]	new[18]	_	_
4-15	293-300	product	abstract[18]	new[18]	_	_
4-16	301-308	quality	abstract[18]	new[18]	_	_
4-17	309-312	has	_	_	_	_
4-18	313-319	turned	_	_	_	_
4-19	320-323	out	_	_	_	_
4-20	324-326	to	_	_	_	_
4-21	327-329	be	_	_	_	_
4-22	330-331	a	abstract[19]	new[19]	_	_
4-23	332-337	major	abstract[19]	new[19]	_	_
4-24	338-345	driving	abstract[19]	new[19]	_	_
4-25	346-351	force	abstract[19]	new[19]	_	_
4-26	352-355	for	abstract[19]	new[19]	_	_
4-27	356-359	the	abstract[19]|abstract[20]	new[19]|giv[20]	_	_
4-28	360-371	development	abstract[19]|abstract[20]	new[19]|giv[20]	_	_
4-29	372-374	of	abstract[19]|abstract[20]	new[19]|giv[20]	_	_
4-30	375-379	flow	abstract[19]|abstract[20]|abstract|abstract[22]	new[19]|giv[20]|giv|giv[22]	coref|coref|coref|coref	5-56|5-56[37_22]|5-56|5-56[37_22]
4-31	380-389	processes	abstract[19]|abstract[20]|abstract[22]	new[19]|giv[20]|giv[22]	_	_
4-32	390-391	.	_	_	_	_

#Text=In particular , for active pharmaceutical ingredients ( APIs ) , this aspect is important , as the FDA along with the EPA , as the respective institutions in United States and Europe for approval of medicines , added aspects of continuous manufacturing to their guidelines , whereas for a long time the focus of flow processes was on “ classic ” chemical processes with , for example , hazardous and thermally labile substances and chemocatalytic reactions .
5-1	392-394	In	_	_	_	_
5-2	395-405	particular	_	_	_	_
5-3	406-407	,	_	_	_	_
5-4	408-411	for	_	_	_	_
5-5	412-418	active	abstract[23]	new[23]	appos	5-9[0_23]
5-6	419-433	pharmaceutical	abstract[23]	new[23]	_	_
5-7	434-445	ingredients	abstract[23]	new[23]	_	_
5-8	446-447	(	_	_	_	_
5-9	448-452	APIs	abstract	giv	_	_
5-10	453-454	)	_	_	_	_
5-11	455-456	,	_	_	_	_
5-12	457-461	this	abstract[25]	new[25]	_	_
5-13	462-468	aspect	abstract[25]	new[25]	_	_
5-14	469-471	is	_	_	_	_
5-15	472-481	important	_	_	_	_
5-16	482-483	,	_	_	_	_
5-17	484-486	as	_	_	_	_
5-18	487-490	the	_	_	_	_
5-19	491-494	FDA	_	_	_	_
5-20	495-500	along	_	_	_	_
5-21	501-505	with	_	_	_	_
5-22	506-509	the	organization[26]	new[26]	_	_
5-23	510-513	EPA	organization[26]	new[26]	_	_
5-24	514-515	,	_	_	_	_
5-25	516-518	as	_	_	_	_
5-26	519-522	the	_	_	_	_
5-27	523-533	respective	_	_	_	_
5-28	534-546	institutions	_	_	_	_
5-29	547-549	in	_	_	_	_
5-30	550-556	United	place[27]	new[27]	_	_
5-31	557-563	States	place[27]	new[27]	_	_
5-32	564-567	and	_	_	_	_
5-33	568-574	Europe	place	new	_	_
5-34	575-578	for	_	_	_	_
5-35	579-587	approval	event[29]	new[29]	_	_
5-36	588-590	of	event[29]	new[29]	_	_
5-37	591-600	medicines	event[29]|substance	new[29]|new	_	_
5-38	601-602	,	_	_	_	_
5-39	603-608	added	_	_	_	_
5-40	609-616	aspects	abstract[31]	new[31]	_	_
5-41	617-619	of	abstract[31]	new[31]	_	_
5-42	620-630	continuous	abstract[31]|abstract[32]	new[31]|new[32]	_	_
5-43	631-644	manufacturing	abstract[31]|abstract[32]	new[31]|new[32]	_	_
5-44	645-647	to	abstract[31]|abstract[32]	new[31]|new[32]	_	_
5-45	648-653	their	abstract[31]|abstract[32]|abstract[33]	new[31]|new[32]|new[33]	_	_
5-46	654-664	guidelines	abstract[31]|abstract[32]|abstract[33]	new[31]|new[32]|new[33]	_	_
5-47	665-666	,	_	_	_	_
5-48	667-674	whereas	time[34]	new[34]	_	_
5-49	675-678	for	time[34]	new[34]	_	_
5-50	679-680	a	time[34]	new[34]	_	_
5-51	681-685	long	time[34]	new[34]	_	_
5-52	686-690	time	time[34]	new[34]	_	_
5-53	691-694	the	abstract[35]	new[35]	_	_
5-54	695-700	focus	abstract[35]	new[35]	_	_
5-55	701-703	of	abstract[35]	new[35]	_	_
5-56	704-708	flow	abstract[35]|abstract|abstract[37]	new[35]|giv|giv[37]	coref|coref|coref|coref	5-63[38_37]|6-5|5-63[38_37]|6-5
5-57	709-718	processes	abstract[35]|abstract[37]	new[35]|giv[37]	_	_
5-58	719-722	was	_	_	_	_
5-59	723-725	on	_	_	_	_
5-60	726-727	“	_	_	_	_
5-61	728-735	classic	_	_	_	_
5-62	736-737	”	_	_	_	_
5-63	738-746	chemical	abstract[38]	giv[38]	coref	6-5[43_38]
5-64	747-756	processes	abstract[38]	giv[38]	_	_
5-65	757-761	with	abstract[38]	giv[38]	_	_
5-66	762-763	,	abstract[38]	giv[38]	_	_
5-67	764-767	for	abstract[38]	giv[38]	_	_
5-68	768-775	example	abstract[38]	giv[38]	_	_
5-69	776-777	,	abstract[38]	giv[38]	_	_
5-70	778-787	hazardous	abstract[38]|substance[39]	giv[38]|new[39]	_	_
5-71	788-791	and	abstract[38]|substance[39]	giv[38]|new[39]	_	_
5-72	792-801	thermally	abstract[38]|substance[39]	giv[38]|new[39]	_	_
5-73	802-808	labile	abstract[38]|substance[39]	giv[38]|new[39]	_	_
5-74	809-819	substances	abstract[38]|substance[39]	giv[38]|new[39]	_	_
5-75	820-823	and	abstract[38]	giv[38]	_	_
5-76	824-838	chemocatalytic	abstract[38]|abstract[40]	giv[38]|new[40]	coref	14-12[110_40]
5-77	839-848	reactions	abstract[38]|abstract[40]	giv[38]|new[40]	_	_
5-78	849-850	.	_	_	_	_

#Text=Recently , biocatalysis in flow processes has become an emerging field with an increasing number of examples .
6-1	851-859	Recently	_	_	_	_
6-2	860-861	,	_	_	_	_
6-3	862-874	biocatalysis	abstract[41]	new[41]	coref	9-11[0_41]
6-4	875-877	in	abstract[41]	new[41]	_	_
6-5	878-882	flow	abstract[41]|abstract|abstract[43]	new[41]|giv|giv[43]	coref|coref|coref|coref	7-11|9-13[72_43]|7-11|9-13[72_43]
6-6	883-892	processes	abstract[41]|abstract[43]	new[41]|giv[43]	_	_
6-7	893-896	has	_	_	_	_
6-8	897-903	become	_	_	_	_
6-9	904-906	an	_	_	_	_
6-10	907-915	emerging	_	_	_	_
6-11	916-921	field	_	_	_	_
6-12	922-926	with	_	_	_	_
6-13	927-929	an	abstract[44]	new[44]	_	_
6-14	930-940	increasing	abstract[44]	new[44]	_	_
6-15	941-947	number	abstract[44]	new[44]	_	_
6-16	948-950	of	abstract[44]	new[44]	_	_
6-17	951-959	examples	abstract[44]|abstract	new[44]|new	coref	7-31[58_0]
6-18	960-961	.	_	_	_	_

#Text=An enzymatic reaction of particular interest for an application in flow mode due to its matured technology level is asymmetric ketone reduction , having a proven track record underlined by many successful examples demonstrated in the past for the batch mode .
7-1	962-964	An	abstract[46]	new[46]	coref	7-20[55_46]
7-2	965-974	enzymatic	abstract[46]	new[46]	_	_
7-3	975-983	reaction	abstract[46]	new[46]	_	_
7-4	984-986	of	abstract[46]	new[46]	_	_
7-5	987-997	particular	abstract[46]|organization[47]	new[46]|giv[47]	_	_
7-6	998-1006	interest	abstract[46]|organization[47]	new[46]|giv[47]	_	_
7-7	1007-1010	for	abstract[46]|organization[47]	new[46]|giv[47]	_	_
7-8	1011-1013	an	abstract[46]|organization[47]|abstract[48]	new[46]|giv[47]|new[48]	coref	11-13[85_48]
7-9	1014-1025	application	abstract[46]|organization[47]|abstract[48]	new[46]|giv[47]|new[48]	_	_
7-10	1026-1028	in	abstract[46]|organization[47]|abstract[48]	new[46]|giv[47]|new[48]	_	_
7-11	1029-1033	flow	abstract[46]|organization[47]|abstract[48]|abstract|abstract[50]	new[46]|giv[47]|new[48]|giv|new[50]	ana|coref|ana|coref	7-15[0_50]|9-13|7-15[0_50]|9-13
7-12	1034-1038	mode	abstract[46]|organization[47]|abstract[48]|abstract[50]	new[46]|giv[47]|new[48]|new[50]	_	_
7-13	1039-1042	due	_	_	_	_
7-14	1043-1045	to	_	_	_	_
7-15	1046-1049	its	abstract|abstract[53]	giv|new[53]	coref|coref	7-39[61_0]|7-39[61_0]
7-16	1050-1057	matured	abstract[53]	new[53]	_	_
7-17	1058-1068	technology	abstract|abstract[53]	new|new[53]	_	_
7-18	1069-1074	level	abstract[53]	new[53]	_	_
7-19	1075-1077	is	_	_	_	_
7-20	1078-1088	asymmetric	abstract[55]	giv[55]	coref	11-20[89_55]
7-21	1089-1095	ketone	substance|abstract[55]	new|giv[55]	coref	10-13
7-22	1096-1105	reduction	abstract[55]	giv[55]	_	_
7-23	1106-1107	,	_	_	_	_
7-24	1108-1114	having	_	_	_	_
7-25	1115-1116	a	abstract[57]	new[57]	_	_
7-26	1117-1123	proven	abstract[57]	new[57]	_	_
7-27	1124-1129	track	place|abstract[57]	new|new[57]	_	_
7-28	1130-1136	record	abstract[57]	new[57]	_	_
7-29	1137-1147	underlined	_	_	_	_
7-30	1148-1150	by	_	_	_	_
7-31	1151-1155	many	abstract[58]	giv[58]	coref	9-9[69_58]
7-32	1156-1166	successful	abstract[58]	giv[58]	_	_
7-33	1167-1175	examples	abstract[58]	giv[58]	_	_
7-34	1176-1188	demonstrated	_	_	_	_
7-35	1189-1191	in	_	_	_	_
7-36	1192-1195	the	time[59]	new[59]	_	_
7-37	1196-1200	past	time[59]	new[59]	_	_
7-38	1201-1204	for	time[59]	new[59]	_	_
7-39	1205-1208	the	time[59]|abstract[61]	new[59]|giv[61]	coref	11-24[90_61]
7-40	1209-1214	batch	time[59]|quantity|abstract[61]	new[59]|giv|giv[61]	_	_
7-41	1215-1219	mode	time[59]|abstract[61]	new[59]|giv[61]	_	_
7-42	1220-1221	.	_	_	_	_

#Text=Recently , significant process in the biocatalytic reductive synthesis of alcohols starting from ketones , as well as syntheses by non-enzymatic means , have been reported .
8-1	1222-1230	Recently	_	_	_	_
8-2	1231-1232	,	_	_	_	_
8-3	1233-1244	significant	event[62]	new[62]	coref	16-7[117_62]
8-4	1245-1252	process	event[62]	new[62]	_	_
8-5	1253-1255	in	event[62]	new[62]	_	_
8-6	1256-1259	the	event[62]|abstract[63]	new[62]|new[63]	_	_
8-7	1260-1272	biocatalytic	event[62]|abstract[63]	new[62]|new[63]	_	_
8-8	1273-1282	reductive	event[62]|abstract[63]	new[62]|new[63]	_	_
8-9	1283-1292	synthesis	event[62]|abstract[63]	new[62]|new[63]	_	_
8-10	1293-1295	of	event[62]|abstract[63]	new[62]|new[63]	_	_
8-11	1296-1304	alcohols	event[62]|abstract[63]|substance	new[62]|new[63]|new	_	_
8-12	1305-1313	starting	event[62]	new[62]	_	_
8-13	1314-1318	from	event[62]	new[62]	_	_
8-14	1319-1326	ketones	event[62]|substance	new[62]|new	_	_
8-15	1327-1328	,	event[62]	new[62]	_	_
8-16	1329-1331	as	event[62]	new[62]	_	_
8-17	1332-1336	well	event[62]	new[62]	_	_
8-18	1337-1339	as	event[62]	new[62]	_	_
8-19	1340-1349	syntheses	event[62]|abstract[66]	new[62]|new[66]	_	_
8-20	1350-1352	by	event[62]|abstract[66]	new[62]|new[66]	_	_
8-21	1353-1366	non-enzymatic	event[62]|abstract[66]	new[62]|new[66]	_	_
8-22	1367-1372	means	_	_	_	_
8-23	1373-1374	,	_	_	_	_
8-24	1375-1379	have	_	_	_	_
8-25	1380-1384	been	_	_	_	_
8-26	1385-1393	reported	_	_	_	_
8-27	1394-1395	.	_	_	_	_

#Text=In recent years , an increasing number of examples of biocatalysis in flow processes have been reported .
9-1	1396-1398	In	_	_	_	_
9-2	1399-1405	recent	time[67]	new[67]	_	_
9-3	1406-1411	years	time[67]	new[67]	_	_
9-4	1412-1413	,	_	_	_	_
9-5	1414-1416	an	abstract[68]	new[68]	_	_
9-6	1417-1427	increasing	abstract[68]	new[68]	_	_
9-7	1428-1434	number	abstract[68]	new[68]	_	_
9-8	1435-1437	of	abstract[68]	new[68]	_	_
9-9	1438-1446	examples	abstract[68]|abstract[69]	new[68]|giv[69]	_	_
9-10	1447-1449	of	abstract[68]|abstract[69]	new[68]|giv[69]	_	_
9-11	1450-1462	biocatalysis	abstract[68]|abstract[69]|abstract	new[68]|giv[69]|giv	_	_
9-12	1463-1465	in	abstract[68]|abstract[69]	new[68]|giv[69]	_	_
9-13	1466-1470	flow	abstract[68]|abstract[69]|abstract|abstract[72]	new[68]|giv[69]|giv|giv[72]	coref|coref|coref|coref	10-23|10-23[81_72]|10-23|10-23[81_72]
9-14	1471-1480	processes	abstract[68]|abstract[69]|abstract[72]	new[68]|giv[69]|giv[72]	_	_
9-15	1481-1485	have	_	_	_	_
9-16	1486-1490	been	_	_	_	_
9-17	1491-1499	reported	_	_	_	_
9-18	1500-1501	.	_	_	_	_

#Text=Although only being studied to a minor extent , some examples of ketone reductions with an alcohol dehydrogenase ( ADH ) in flow processes have been described .
10-1	1502-1510	Although	_	_	_	_
10-2	1511-1515	only	_	_	_	_
10-3	1516-1521	being	_	_	_	_
10-4	1522-1529	studied	_	_	_	_
10-5	1530-1532	to	_	_	_	_
10-6	1533-1534	a	abstract[73]	new[73]	_	_
10-7	1535-1540	minor	abstract[73]	new[73]	_	_
10-8	1541-1547	extent	abstract[73]	new[73]	_	_
10-9	1548-1549	,	_	_	_	_
10-10	1550-1554	some	abstract[74]	new[74]	_	_
10-11	1555-1563	examples	abstract[74]	new[74]	_	_
10-12	1564-1566	of	abstract[74]	new[74]	_	_
10-13	1567-1573	ketone	abstract[74]|substance|abstract[76]	new[74]|giv|new[76]	coref|coref	11-21|11-21
10-14	1574-1584	reductions	abstract[74]|abstract[76]	new[74]|new[76]	_	_
10-15	1585-1589	with	abstract[74]|abstract[76]	new[74]|new[76]	_	_
10-16	1590-1592	an	abstract[74]|abstract[76]|abstract[78]	new[74]|new[76]|new[78]	appos	10-20[0_78]
10-17	1593-1600	alcohol	abstract[74]|abstract[76]|substance|abstract[78]	new[74]|new[76]|new|new[78]	_	_
10-18	1601-1614	dehydrogenase	abstract[74]|abstract[76]|abstract[78]	new[74]|new[76]|new[78]	_	_
10-19	1615-1616	(	_	_	_	_
10-20	1617-1620	ADH	abstract	giv	coref	11-40[95_0]
10-21	1621-1622	)	_	_	_	_
10-22	1623-1625	in	_	_	_	_
10-23	1626-1630	flow	abstract|abstract[81]	giv|giv[81]	coref|coref|coref|coref	13-10|17-2[122_81]|13-10|17-2[122_81]
10-24	1631-1640	processes	abstract[81]	giv[81]	_	_
10-25	1641-1645	have	_	_	_	_
10-26	1646-1650	been	_	_	_	_
10-27	1651-1660	described	_	_	_	_
10-28	1661-1662	.	_	_	_	_

#Text=For example , Wandrey ’s and Liese ’s groups studied in detail the application of enzyme membrane reactors for enzymatic ketone reduction in a continuously running mode , and packed bed reactor setups were described by further groups using carrier-bound ADH from Lactobacillus brevis ( LB-ADH ) in combination with a mobile aqueous phase , or magnetic nanoparticle-bound ADH .
11-1	1663-1666	For	_	_	_	_
11-2	1667-1674	example	_	_	_	_
11-3	1675-1676	,	_	_	_	_
11-4	1677-1684	Wandrey	person[82]|person[84]	new[82]|new[84]	coref|coref	11-37[94_84]|11-37[94_84]
11-5	1685-1687	’s	person[82]|person[84]	new[82]|new[84]	_	_
11-6	1688-1691	and	person[84]	new[84]	_	_
11-7	1692-1697	Liese	person[83]|person[84]	new[83]|new[84]	_	_
11-8	1698-1700	’s	person[83]|person[84]	new[83]|new[84]	_	_
11-9	1701-1707	groups	person[84]	new[84]	_	_
11-10	1708-1715	studied	_	_	_	_
11-11	1716-1718	in	_	_	_	_
11-12	1719-1725	detail	_	_	_	_
11-13	1726-1729	the	abstract[85]	giv[85]	coref	30-8[213_85]
11-14	1730-1741	application	abstract[85]	giv[85]	_	_
11-15	1742-1744	of	abstract[85]	giv[85]	_	_
11-16	1745-1751	enzyme	abstract[85]|object[87]	giv[85]|new[87]	coref	17-5[124_87]
11-17	1752-1760	membrane	abstract[85]|substance|object[87]	giv[85]|new|new[87]	_	_
11-18	1761-1769	reactors	abstract[85]|object[87]	giv[85]|new[87]	_	_
11-19	1770-1773	for	abstract[85]|object[87]	giv[85]|new[87]	_	_
11-20	1774-1783	enzymatic	abstract[85]|object[87]|abstract[89]	giv[85]|new[87]|giv[89]	coref	15-9[0_89]
11-21	1784-1790	ketone	abstract[85]|object[87]|substance|abstract[89]	giv[85]|new[87]|giv|giv[89]	_	_
11-22	1791-1800	reduction	abstract[85]|object[87]|abstract[89]	giv[85]|new[87]|giv[89]	_	_
11-23	1801-1803	in	abstract[85]|object[87]|abstract[89]	giv[85]|new[87]|giv[89]	_	_
11-24	1804-1805	a	abstract[85]|object[87]|abstract[89]|abstract[90]	giv[85]|new[87]|giv[89]|giv[90]	_	_
11-25	1806-1818	continuously	abstract[85]|object[87]|abstract[89]|abstract[90]	giv[85]|new[87]|giv[89]|giv[90]	_	_
11-26	1819-1826	running	abstract[85]|object[87]|abstract[89]|abstract[90]	giv[85]|new[87]|giv[89]|giv[90]	_	_
11-27	1827-1831	mode	abstract[85]|object[87]|abstract[89]|abstract[90]	giv[85]|new[87]|giv[89]|giv[90]	_	_
11-28	1832-1833	,	_	_	_	_
11-29	1834-1837	and	_	_	_	_
11-30	1838-1844	packed	_	_	_	_
11-31	1845-1848	bed	object|abstract[93]	new|new[93]	coref|coref	17-6|17-6
11-32	1849-1856	reactor	object|abstract[93]	new|new[93]	coref	30-11[215_0]
11-33	1857-1863	setups	abstract[93]	new[93]	_	_
11-34	1864-1868	were	_	_	_	_
11-35	1869-1878	described	_	_	_	_
11-36	1879-1881	by	_	_	_	_
11-37	1882-1889	further	person[94]	giv[94]	_	_
11-38	1890-1896	groups	person[94]	giv[94]	_	_
11-39	1897-1902	using	_	_	_	_
11-40	1903-1916	carrier-bound	abstract[95]	giv[95]	coref	11-57[100_95]
11-41	1917-1920	ADH	abstract[95]	giv[95]	_	_
11-42	1921-1925	from	_	_	_	_
11-43	1926-1939	Lactobacillus	abstract	new	_	_
11-44	1940-1946	brevis	_	_	_	_
11-45	1947-1948	(	_	_	_	_
11-46	1949-1955	LB-ADH	abstract	new	coref	39-10
11-47	1956-1957	)	_	_	_	_
11-48	1958-1960	in	_	_	_	_
11-49	1961-1972	combination	abstract[98]	new[98]	_	_
11-50	1973-1977	with	abstract[98]	new[98]	_	_
11-51	1978-1979	a	abstract[98]|abstract[99]	new[98]|new[99]	coref	30-29[0_99]
11-52	1980-1986	mobile	abstract[98]|abstract[99]	new[98]|new[99]	_	_
11-53	1987-1994	aqueous	abstract[98]|abstract[99]	new[98]|new[99]	_	_
11-54	1995-2000	phase	abstract[98]|abstract[99]	new[98]|new[99]	_	_
11-55	2001-2002	,	abstract[98]	new[98]	_	_
11-56	2003-2005	or	abstract[98]	new[98]	_	_
11-57	2006-2014	magnetic	abstract[98]|abstract[100]	new[98]|giv[100]	coref	13-6[0_100]
11-58	2015-2033	nanoparticle-bound	abstract[98]|abstract[100]	new[98]|giv[100]	_	_
11-59	2034-2037	ADH	abstract[98]|abstract[100]	new[98]|giv[100]	_	_
11-60	2038-2039	.	_	_	_	_

#Text=In addition , Buehler et al.
12-1	2040-2042	In	_	_	_	_
12-2	2043-2051	addition	_	_	_	_
12-3	2052-2053	,	_	_	_	_
12-4	2054-2061	Buehler	person	new	_	_
12-5	2062-2064	et	_	_	_	_
12-6	2065-2068	al.	_	_	_	_

#Text=investigated intensively the use of ADH in aqueous/organic segmented flow systems .
13-1	2069-2081	investigated	_	_	_	_
13-2	2082-2093	intensively	_	_	_	_
13-3	2094-2097	the	abstract[102]	new[102]	ana	14-1[0_102]
13-4	2098-2101	use	abstract[102]	new[102]	_	_
13-5	2102-2104	of	abstract[102]	new[102]	_	_
13-6	2105-2108	ADH	abstract[102]|abstract	new[102]|giv	coref	28-5[199_0]
13-7	2109-2111	in	abstract[102]	new[102]	_	_
13-8	2112-2127	aqueous/organic	abstract[102]|abstract[105]	new[102]|new[105]	_	_
13-9	2128-2137	segmented	abstract[102]|abstract[105]	new[102]|new[105]	_	_
13-10	2138-2142	flow	abstract[102]|abstract|abstract[105]	new[102]|giv|new[105]	coref	16-17
13-11	2143-2150	systems	abstract[102]|abstract[105]	new[102]|new[105]	_	_
13-12	2151-2152	.	_	_	_	_

#Text=It was shown that emulsion formation could be eliminated , and enzymatic mass transfer-limited reactions can be enhanced .
14-1	2153-2155	It	abstract	giv	_	_
14-2	2156-2159	was	_	_	_	_
14-3	2160-2165	shown	_	_	_	_
14-4	2166-2170	that	_	_	_	_
14-5	2171-2179	emulsion	substance|abstract[108]	new|new[108]	_	_
14-6	2180-2189	formation	abstract[108]	new[108]	_	_
14-7	2190-2195	could	_	_	_	_
14-8	2196-2198	be	_	_	_	_
14-9	2199-2209	eliminated	_	_	_	_
14-10	2210-2211	,	_	_	_	_
14-11	2212-2215	and	_	_	_	_
14-12	2216-2225	enzymatic	abstract[110]	giv[110]	_	_
14-13	2226-2230	mass	quantity|abstract[110]	new|giv[110]	coref	30-25
14-14	2231-2247	transfer-limited	abstract[110]	giv[110]	_	_
14-15	2248-2257	reactions	abstract[110]	giv[110]	_	_
14-16	2258-2261	can	_	_	_	_
14-17	2262-2264	be	_	_	_	_
14-18	2265-2273	enhanced	_	_	_	_
14-19	2274-2275	.	_	_	_	_

#Text=Furthermore , different means of stabilization of this reaction system were investigated .
15-1	2276-2287	Furthermore	_	_	_	_
15-2	2288-2289	,	_	_	_	_
15-3	2290-2299	different	abstract[111]	new[111]	_	_
15-4	2300-2305	means	abstract[111]	new[111]	_	_
15-5	2306-2308	of	abstract[111]	new[111]	_	_
15-6	2309-2322	stabilization	abstract[111]|abstract[112]	new[111]|new[112]	_	_
15-7	2323-2325	of	abstract[111]|abstract[112]	new[111]|new[112]	_	_
15-8	2326-2330	this	abstract[111]|abstract[112]|abstract[114]	new[111]|new[112]|new[114]	_	_
15-9	2331-2339	reaction	abstract[111]|abstract[112]|abstract|abstract[114]	new[111]|new[112]|giv|new[114]	_	_
15-10	2340-2346	system	abstract[111]|abstract[112]|abstract[114]	new[111]|new[112]|new[114]	_	_
15-11	2347-2351	were	_	_	_	_
15-12	2352-2364	investigated	_	_	_	_
15-13	2365-2366	.	_	_	_	_

#Text=Very recently , our group published an improved downstream process by means of such a segmented flow process , illustrated using two different ADHs and substrates .
16-1	2367-2371	Very	_	_	_	_
16-2	2372-2380	recently	_	_	_	_
16-3	2381-2382	,	_	_	_	_
16-4	2383-2386	our	person|organization[116]	acc|new[116]	_	_
16-5	2387-2392	group	organization[116]	new[116]	_	_
16-6	2393-2402	published	_	_	_	_
16-7	2403-2405	an	event[117]	giv[117]	coref	16-14[119_117]
16-8	2406-2414	improved	event[117]	giv[117]	_	_
16-9	2415-2425	downstream	event[117]	giv[117]	_	_
16-10	2426-2433	process	event[117]	giv[117]	_	_
16-11	2434-2436	by	_	_	_	_
16-12	2437-2442	means	_	_	_	_
16-13	2443-2445	of	_	_	_	_
16-14	2446-2450	such	event[119]	giv[119]	coref	20-11[141_119]
16-15	2451-2452	a	event[119]	giv[119]	_	_
16-16	2453-2462	segmented	event[119]	giv[119]	_	_
16-17	2463-2467	flow	abstract|event[119]	giv|giv[119]	_	_
16-18	2468-2475	process	event[119]	giv[119]	_	_
16-19	2476-2477	,	_	_	_	_
16-20	2478-2489	illustrated	_	_	_	_
16-21	2490-2495	using	_	_	_	_
16-22	2496-2499	two	abstract[120]	new[120]	coref	27-11[0_120]
16-23	2500-2509	different	abstract[120]	new[120]	_	_
16-24	2510-2514	ADHs	abstract[120]	new[120]	_	_
16-25	2515-2518	and	_	_	_	_
16-26	2519-2529	substrates	object	new	_	_
16-27	2530-2531	.	_	_	_	_

#Text=In continuous processes using packed bed reactors ( PBR ) , catalyst immobilization is a prerequisite .
17-1	2532-2534	In	_	_	_	_
17-2	2535-2545	continuous	abstract[122]	giv[122]	coref	18-3[129_122]
17-3	2546-2555	processes	abstract[122]	giv[122]	_	_
17-4	2556-2561	using	_	_	_	_
17-5	2562-2568	packed	object[124]	giv[124]	appos	17-9[0_124]
17-6	2569-2572	bed	place|object[124]	giv|giv[124]	coref	30-13
17-7	2573-2581	reactors	object[124]	giv[124]	_	_
17-8	2582-2583	(	_	_	_	_
17-9	2584-2587	PBR	object	giv	_	_
17-10	2588-2589	)	_	_	_	_
17-11	2590-2591	,	_	_	_	_
17-12	2592-2600	catalyst	abstract|abstract[127]	new|new[127]	coref|coref|coref|coref	17-15[128_127]|18-16[133_0]|17-15[128_127]|18-16[133_0]
17-13	2601-2615	immobilization	abstract[127]	new[127]	_	_
17-14	2616-2618	is	_	_	_	_
17-15	2619-2620	a	abstract[128]	giv[128]	coref	18-7[0_128]
17-16	2621-2633	prerequisite	abstract[128]	giv[128]	_	_
17-17	2634-2635	.	_	_	_	_

#Text=Also , downstream processes benefit from immobilization , as separation of the reaction mixture from the catalyst is easier , and the catalyst reusability is improved .
18-1	2636-2640	Also	_	_	_	_
18-2	2641-2642	,	_	_	_	_
18-3	2643-2653	downstream	abstract[129]	giv[129]	_	_
18-4	2654-2663	processes	abstract[129]	giv[129]	_	_
18-5	2664-2671	benefit	_	_	_	_
18-6	2672-2676	from	_	_	_	_
18-7	2677-2691	immobilization	abstract	giv	coref	20-12
18-8	2692-2693	,	_	_	_	_
18-9	2694-2696	as	_	_	_	_
18-10	2697-2707	separation	event[131]	new[131]	_	_
18-11	2708-2710	of	event[131]	new[131]	_	_
18-12	2711-2714	the	event[131]|substance[132]	new[131]|new[132]	_	_
18-13	2715-2723	reaction	event[131]|substance[132]	new[131]|new[132]	_	_
18-14	2724-2731	mixture	event[131]|substance[132]	new[131]|new[132]	_	_
18-15	2732-2736	from	event[131]|substance[132]	new[131]|new[132]	_	_
18-16	2737-2740	the	event[131]|substance[132]|abstract[133]	new[131]|new[132]|giv[133]	coref	19-13[137_133]
18-17	2741-2749	catalyst	event[131]|substance[132]|abstract[133]	new[131]|new[132]|giv[133]	_	_
18-18	2750-2752	is	_	_	_	_
18-19	2753-2759	easier	_	_	_	_
18-20	2760-2761	,	_	_	_	_
18-21	2762-2765	and	_	_	_	_
18-22	2766-2769	the	abstract[134]	new[134]	_	_
18-23	2770-2778	catalyst	abstract[134]	new[134]	_	_
18-24	2779-2790	reusability	abstract[134]	new[134]	_	_
18-25	2791-2793	is	_	_	_	_
18-26	2794-2802	improved	_	_	_	_
18-27	2803-2804	.	_	_	_	_

#Text=Moreover , both , operational , as well as storage stability of the catalyst can potentially be significantly increased .
19-1	2805-2813	Moreover	_	_	_	_
19-2	2814-2815	,	_	_	_	_
19-3	2816-2820	both	_	_	_	_
19-4	2821-2822	,	_	_	_	_
19-5	2823-2834	operational	_	_	_	_
19-6	2835-2836	,	_	_	_	_
19-7	2837-2839	as	_	_	_	_
19-8	2840-2844	well	_	_	_	_
19-9	2845-2847	as	_	_	_	_
19-10	2848-2855	storage	place|abstract[136]	new|new[136]	_	_
19-11	2856-2865	stability	abstract[136]	new[136]	_	_
19-12	2866-2868	of	abstract[136]	new[136]	_	_
19-13	2869-2872	the	abstract[136]|object[137]	new[136]|giv[137]	coref	20-23[144_137]
19-14	2873-2881	catalyst	abstract[136]|object[137]	new[136]|giv[137]	_	_
19-15	2882-2885	can	_	_	_	_
19-16	2886-2897	potentially	_	_	_	_
19-17	2898-2900	be	_	_	_	_
19-18	2901-2914	significantly	_	_	_	_
19-19	2915-2924	increased	_	_	_	_
19-20	2925-2926	.	_	_	_	_

#Text=However , often a significant loss of enzymatic activity during the immobilization process represents a drawback , and the reproducible production of immobilized catalyst may be a further challenge .
20-1	2927-2934	However	_	_	_	_
20-2	2935-2936	,	_	_	_	_
20-3	2937-2942	often	_	_	_	_
20-4	2943-2944	a	abstract[138]	new[138]	coref	28-18[202_138]
20-5	2945-2956	significant	abstract[138]	new[138]	_	_
20-6	2957-2961	loss	abstract[138]	new[138]	_	_
20-7	2962-2964	of	abstract[138]	new[138]	_	_
20-8	2965-2974	enzymatic	abstract[138]|abstract[139]	new[138]|new[139]	coref	28-22[0_139]
20-9	2975-2983	activity	abstract[138]|abstract[139]	new[138]|new[139]	_	_
20-10	2984-2990	during	abstract[138]|abstract[139]	new[138]|new[139]	_	_
20-11	2991-2994	the	abstract[138]|abstract[139]|event[141]	new[138]|new[139]|giv[141]	_	_
20-12	2995-3009	immobilization	abstract[138]|abstract[139]|abstract|event[141]	new[138]|new[139]|giv|giv[141]	coref	22-9[167_0]
20-13	3010-3017	process	abstract[138]|abstract[139]|event[141]	new[138]|new[139]|giv[141]	_	_
20-14	3018-3028	represents	_	_	_	_
20-15	3029-3030	a	abstract[142]	new[142]	_	_
20-16	3031-3039	drawback	abstract[142]	new[142]	_	_
20-17	3040-3041	,	_	_	_	_
20-18	3042-3045	and	_	_	_	_
20-19	3046-3049	the	abstract[143]	new[143]	coref	20-27[145_143]
20-20	3050-3062	reproducible	abstract[143]	new[143]	_	_
20-21	3063-3073	production	abstract[143]	new[143]	_	_
20-22	3074-3076	of	abstract[143]	new[143]	_	_
20-23	3077-3088	immobilized	abstract[143]|abstract[144]	new[143]|giv[144]	coref	29-23[0_144]
20-24	3089-3097	catalyst	abstract[143]|abstract[144]	new[143]|giv[144]	_	_
20-25	3098-3101	may	_	_	_	_
20-26	3102-3104	be	_	_	_	_
20-27	3105-3106	a	abstract[145]	giv[145]	_	_
20-28	3107-3114	further	abstract[145]	giv[145]	_	_
20-29	3115-3124	challenge	abstract[145]	giv[145]	_	_
20-30	3125-3126	.	_	_	_	_

#Text=Numerous techniques have been developed over the past years , which can be classified in the following three major methods : ( a ) binding to a solid support ( carrier ) , ( b ) entrapment ( encapsulation ) in polymer networks , or ( c ) cross-linking in the form of cross-linked enzyme aggregates ( CLEAs ) or cross-linked enzyme crystals ( CLECs ) .
21-1	3127-3135	Numerous	abstract[146]	new[146]	_	_
21-2	3136-3146	techniques	abstract[146]	new[146]	_	_
21-3	3147-3151	have	_	_	_	_
21-4	3152-3156	been	_	_	_	_
21-5	3157-3166	developed	_	_	_	_
21-6	3167-3171	over	_	_	_	_
21-7	3172-3175	the	time[147]	new[147]	_	_
21-8	3176-3180	past	time[147]	new[147]	_	_
21-9	3181-3186	years	time[147]	new[147]	_	_
21-10	3187-3188	,	_	_	_	_
21-11	3189-3194	which	_	_	_	_
21-12	3195-3198	can	_	_	_	_
21-13	3199-3201	be	_	_	_	_
21-14	3202-3212	classified	_	_	_	_
21-15	3213-3215	in	_	_	_	_
21-16	3216-3219	the	abstract[148]	new[148]	_	_
21-17	3220-3229	following	abstract[148]	new[148]	_	_
21-18	3230-3235	three	abstract[148]	new[148]	_	_
21-19	3236-3241	major	abstract[148]	new[148]	_	_
21-20	3242-3249	methods	abstract[148]	new[148]	_	_
21-21	3250-3251	:	abstract[148]	new[148]	_	_
21-22	3252-3253	(	abstract[148]	new[148]	_	_
21-23	3254-3255	a	abstract[148]	new[148]	_	_
21-24	3256-3257	)	abstract[148]	new[148]	_	_
21-25	3258-3265	binding	_	_	_	_
21-26	3266-3268	to	_	_	_	_
21-27	3269-3270	a	abstract[149]	new[149]	coref	26-22[190_149]
21-28	3271-3276	solid	abstract[149]	new[149]	_	_
21-29	3277-3284	support	abstract[149]	new[149]	_	_
21-30	3285-3286	(	_	_	_	_
21-31	3287-3294	carrier	organization	new	_	_
21-32	3295-3296	)	_	_	_	_
21-33	3297-3298	,	_	_	_	_
21-34	3299-3300	(	_	_	_	_
21-35	3301-3302	b	abstract	new	appos	21-39
21-36	3303-3304	)	_	_	_	_
21-37	3305-3315	entrapment	abstract	new	coref	23-8[170_0]
21-38	3316-3317	(	_	_	_	_
21-39	3318-3331	encapsulation	abstract	giv	_	_
21-40	3332-3333	)	_	_	_	_
21-41	3334-3336	in	_	_	_	_
21-42	3337-3344	polymer	person|place[155]	new|new[155]	coref|coref|coref|coref	23-12|23-12[173_155]|23-12|23-12[173_155]
21-43	3345-3353	networks	place[155]	new[155]	_	_
21-44	3354-3355	,	_	_	_	_
21-45	3356-3358	or	_	_	_	_
21-46	3359-3360	(	_	_	_	_
21-47	3361-3362	c	abstract	new	_	_
21-48	3363-3364	)	_	_	_	_
21-49	3365-3378	cross-linking	_	_	_	_
21-50	3379-3381	in	_	_	_	_
21-51	3382-3385	the	substance[157]	new[157]	coref	27-21[197_157]
21-52	3386-3390	form	substance[157]	new[157]	_	_
21-53	3391-3393	of	substance[157]	new[157]	_	_
21-54	3394-3406	cross-linked	substance[157]|abstract[159]	new[157]|new[159]	appos	21-58[0_159]
21-55	3407-3413	enzyme	substance[157]|substance|abstract[159]	new[157]|new|new[159]	coref	21-62
21-56	3414-3424	aggregates	substance[157]|abstract[159]	new[157]|new[159]	_	_
21-57	3425-3426	(	_	_	_	_
21-58	3427-3432	CLEAs	abstract	giv	_	_
21-59	3433-3434	)	_	_	_	_
21-60	3435-3437	or	_	_	_	_
21-61	3438-3450	cross-linked	object[162]	new[162]	_	_
21-62	3451-3457	enzyme	substance|object[162]	giv|new[162]	coref	22-9
21-63	3458-3466	crystals	object[162]	new[162]	_	_
21-64	3467-3468	(	_	_	_	_
21-65	3469-3474	CLECs	abstract	new	_	_
21-66	3475-3476	)	_	_	_	_
21-67	3477-3478	.	_	_	_	_

#Text=Recently , much progress in the field of enzyme immobilization has been made .
22-1	3479-3487	Recently	_	_	_	_
22-2	3488-3489	,	_	_	_	_
22-3	3490-3494	much	abstract[164]	new[164]	_	_
22-4	3495-3503	progress	abstract[164]	new[164]	_	_
22-5	3504-3506	in	abstract[164]	new[164]	_	_
22-6	3507-3510	the	abstract[164]|abstract[165]	new[164]|new[165]	_	_
22-7	3511-3516	field	abstract[164]|abstract[165]	new[164]|new[165]	_	_
22-8	3517-3519	of	abstract[164]|abstract[165]	new[164]|new[165]	_	_
22-9	3520-3526	enzyme	abstract[164]|abstract[165]|substance|abstract[167]	new[164]|new[165]|giv|giv[167]	coref|coref|coref|coref	26-5[184_0]|29-13[0_167]|26-5[184_0]|29-13[0_167]
22-10	3527-3541	immobilization	abstract[164]|abstract[165]|abstract[167]	new[164]|new[165]|giv[167]	_	_
22-11	3542-3545	has	_	_	_	_
22-12	3546-3550	been	_	_	_	_
22-13	3551-3555	made	_	_	_	_
22-14	3556-3557	.	_	_	_	_

#Text=In this work , the option of entrapment of enzymes in polymer networks has been chosen .
23-1	3558-3560	In	_	_	_	_
23-2	3561-3565	this	abstract[168]	new[168]	_	_
23-3	3566-3570	work	abstract[168]	new[168]	_	_
23-4	3571-3572	,	_	_	_	_
23-5	3573-3576	the	abstract[169]	new[169]	_	_
23-6	3577-3583	option	abstract[169]	new[169]	_	_
23-7	3584-3586	of	abstract[169]	new[169]	_	_
23-8	3587-3597	entrapment	abstract[169]|abstract[170]	new[169]|giv[170]	_	_
23-9	3598-3600	of	abstract[169]|abstract[170]	new[169]|giv[170]	_	_
23-10	3601-3608	enzymes	abstract[169]|abstract[170]|substance[171]	new[169]|giv[170]|new[171]	_	_
23-11	3609-3611	in	abstract[169]|abstract[170]|substance[171]	new[169]|giv[170]|new[171]	_	_
23-12	3612-3619	polymer	abstract[169]|abstract[170]|substance[171]|person|place[173]	new[169]|giv[170]|new[171]|giv|giv[173]	coref|coref	31-1[224_0]|31-1[224_0]
23-13	3620-3628	networks	abstract[169]|abstract[170]|substance[171]|place[173]	new[169]|giv[170]|new[171]|giv[173]	_	_
23-14	3629-3632	has	_	_	_	_
23-15	3633-3637	been	_	_	_	_
23-16	3638-3644	chosen	_	_	_	_
23-17	3645-3646	.	_	_	_	_

#Text=Often for this purpose , organic polymers containing cavities , sol-gel-processed particles , or membranes are used .
24-1	3647-3652	Often	_	_	_	_
24-2	3653-3656	for	_	_	_	_
24-3	3657-3661	this	abstract[174]	new[174]	_	_
24-4	3662-3669	purpose	abstract[174]	new[174]	_	_
24-5	3670-3671	,	_	_	_	_
24-6	3672-3679	organic	substance[175]	new[175]	coref	25-8[181_175]
24-7	3680-3688	polymers	substance[175]	new[175]	_	_
24-8	3689-3699	containing	_	_	_	_
24-9	3700-3708	cavities	object	new	_	_
24-10	3709-3710	,	_	_	_	_
24-11	3711-3728	sol-gel-processed	object[177]	new[177]	_	_
24-12	3729-3738	particles	object[177]	new[177]	_	_
24-13	3739-3740	,	_	_	_	_
24-14	3741-3743	or	_	_	_	_
24-15	3744-3753	membranes	object	new	_	_
24-16	3754-3757	are	_	_	_	_
24-17	3758-3762	used	_	_	_	_
24-18	3763-3764	.	_	_	_	_

#Text=A special case is the use of superabsorbent polymers to immobilize the entire aqueous phase. .
25-1	3765-3766	A	abstract[179]	new[179]	coref	25-5[180_179]
25-2	3767-3774	special	abstract[179]	new[179]	_	_
25-3	3775-3779	case	abstract[179]	new[179]	_	_
25-4	3780-3782	is	_	_	_	_
25-5	3783-3786	the	abstract[180]	giv[180]	coref	26-2[183_180]
25-6	3787-3790	use	abstract[180]	giv[180]	_	_
25-7	3791-3793	of	abstract[180]	giv[180]	_	_
25-8	3794-3808	superabsorbent	abstract[180]|substance[181]	giv[180]|giv[181]	_	_
25-9	3809-3817	polymers	abstract[180]|substance[181]	giv[180]|giv[181]	_	_
25-10	3818-3820	to	_	_	_	_
25-11	3821-3831	immobilize	_	_	_	_
25-12	3832-3835	the	substance[182]	new[182]	_	_
25-13	3836-3842	entire	substance[182]	new[182]	_	_
25-14	3843-3850	aqueous	substance[182]	new[182]	_	_
25-15	3851-3857	phase.	substance[182]	new[182]	_	_
25-16	3858-3859	.	_	_	_	_

#Text=In this case , the enzyme is immobilized in its native aqueous environment , whereby undesired interactions of protein moieties with the support can be prevented .
26-1	3860-3862	In	_	_	_	_
26-2	3863-3867	this	abstract[183]	giv[183]	ana	26-10[0_183]
26-3	3868-3872	case	abstract[183]	giv[183]	_	_
26-4	3873-3874	,	_	_	_	_
26-5	3875-3878	the	substance[184]	giv[184]	coref	36-6[247_184]
26-6	3879-3885	enzyme	substance[184]	giv[184]	_	_
26-7	3886-3888	is	_	_	_	_
26-8	3889-3900	immobilized	_	_	_	_
26-9	3901-3903	in	_	_	_	_
26-10	3904-3907	its	abstract|place[186]	giv|new[186]	_	_
26-11	3908-3914	native	place[186]	new[186]	_	_
26-12	3915-3922	aqueous	place[186]	new[186]	_	_
26-13	3923-3934	environment	place[186]	new[186]	_	_
26-14	3935-3936	,	_	_	_	_
26-15	3937-3944	whereby	_	_	_	_
26-16	3945-3954	undesired	abstract[187]	new[187]	_	_
26-17	3955-3967	interactions	abstract[187]	new[187]	_	_
26-18	3968-3970	of	abstract[187]	new[187]	_	_
26-19	3971-3978	protein	abstract[187]|substance|substance[189]	new[187]|new|new[189]	coref|coref|coref|coref	32-21[232_189]|32-30[236_0]|32-21[232_189]|32-30[236_0]
26-20	3979-3987	moieties	abstract[187]|substance[189]	new[187]|new[189]	_	_
26-21	3988-3992	with	abstract[187]|substance[189]	new[187]|new[189]	_	_
26-22	3993-3996	the	abstract[187]|substance[189]|abstract[190]	new[187]|new[189]|giv[190]	_	_
26-23	3997-4004	support	abstract[187]|substance[189]|abstract[190]	new[187]|new[189]|giv[190]	_	_
26-24	4005-4008	can	_	_	_	_
26-25	4009-4011	be	_	_	_	_
26-26	4012-4021	prevented	_	_	_	_
26-27	4022-4023	.	_	_	_	_

#Text=Recently , Gröger et al. applied a method of immobilizing ADHs with superabsorber efficiently for the synthesis of diols in enantiomerically pure form .
27-1	4024-4032	Recently	_	_	_	_
27-2	4033-4034	,	_	_	_	_
27-3	4035-4041	Gröger	person	new	_	_
27-4	4042-4044	et	_	_	_	_
27-5	4045-4048	al.	_	_	_	_
27-6	4049-4056	applied	_	_	_	_
27-7	4057-4058	a	abstract[192]	new[192]	coref	29-3[205_192]
27-8	4059-4065	method	abstract[192]	new[192]	_	_
27-9	4066-4068	of	_	_	_	_
27-10	4069-4081	immobilizing	_	_	_	_
27-11	4082-4086	ADHs	abstract	giv	_	_
27-12	4087-4091	with	_	_	_	_
27-13	4092-4105	superabsorber	substance	new	coref	34-13
27-14	4106-4117	efficiently	_	_	_	_
27-15	4118-4121	for	_	_	_	_
27-16	4122-4125	the	event[195]	new[195]	_	_
27-17	4126-4135	synthesis	event[195]	new[195]	_	_
27-18	4136-4138	of	event[195]	new[195]	_	_
27-19	4139-4144	diols	event[195]|substance[196]	new[195]|new[196]	_	_
27-20	4145-4147	in	event[195]|substance[196]	new[195]|new[196]	_	_
27-21	4148-4164	enantiomerically	event[195]|substance[196]|substance[197]	new[195]|new[196]|giv[197]	_	_
27-22	4165-4169	pure	event[195]|substance[196]|substance[197]	new[195]|new[196]|giv[197]	_	_
27-23	4170-4174	form	event[195]|substance[196]|substance[197]	new[195]|new[196]|giv[197]	_	_
27-24	4175-4176	.	_	_	_	_

#Text=In this example , the immobilized ADH from Rhodococcus sp . was used in organic solvents without a major loss in activity .
28-1	4177-4179	In	_	_	_	_
28-2	4180-4184	this	abstract[198]	new[198]	_	_
28-3	4185-4192	example	abstract[198]	new[198]	_	_
28-4	4193-4194	,	_	_	_	_
28-5	4195-4198	the	abstract[199]	giv[199]	coref	39-5[255_199]
28-6	4199-4210	immobilized	abstract[199]	giv[199]	_	_
28-7	4211-4214	ADH	abstract[199]	giv[199]	_	_
28-8	4215-4219	from	abstract[199]	giv[199]	_	_
28-9	4220-4231	Rhodococcus	abstract[199]|abstract[200]	giv[199]|new[200]	_	_
28-10	4232-4234	sp	abstract[199]|abstract[200]	giv[199]|new[200]	_	_
28-11	4235-4236	.	_	_	_	_
28-12	4237-4240	was	_	_	_	_
28-13	4241-4245	used	_	_	_	_
28-14	4246-4248	in	_	_	_	_
28-15	4249-4256	organic	substance[201]	new[201]	coref	41-7[267_201]
28-16	4257-4265	solvents	substance[201]	new[201]	_	_
28-17	4266-4273	without	_	_	_	_
28-18	4274-4275	a	abstract[202]	giv[202]	_	_
28-19	4276-4281	major	abstract[202]	giv[202]	_	_
28-20	4282-4286	loss	abstract[202]	giv[202]	_	_
28-21	4287-4289	in	abstract[202]	giv[202]	_	_
28-22	4290-4298	activity	abstract[202]|abstract	giv[202]|giv	_	_
28-23	4299-4300	.	_	_	_	_

#Text=Advantages of this method is the low cost , the very fast immobilization procedure ( <30 min ) , and the excellent catalyst reusability .
29-1	4301-4311	Advantages	abstract[204]	new[204]	coref	29-6[206_204]
29-2	4312-4314	of	abstract[204]	new[204]	_	_
29-3	4315-4319	this	abstract[204]|abstract[205]	new[204]|giv[205]	_	_
29-4	4320-4326	method	abstract[204]|abstract[205]	new[204]|giv[205]	_	_
29-5	4327-4329	is	_	_	_	_
29-6	4330-4333	the	abstract[206]	giv[206]	appos	29-10[208_206]
29-7	4334-4337	low	abstract[206]	giv[206]	_	_
29-8	4338-4342	cost	abstract[206]	giv[206]	_	_
29-9	4343-4344	,	_	_	_	_
29-10	4345-4348	the	abstract[208]	giv[208]	appos	29-21[211_208]
29-11	4349-4353	very	abstract[208]	giv[208]	_	_
29-12	4354-4358	fast	abstract[208]	giv[208]	_	_
29-13	4359-4373	immobilization	abstract|abstract[208]	giv|giv[208]	_	_
29-14	4374-4383	procedure	abstract[208]	giv[208]	_	_
29-15	4384-4385	(	_	_	_	_
29-16	4386-4389	<30	time[209]	new[209]	_	_
29-17	4390-4393	min	time[209]	new[209]	_	_
29-18	4394-4395	)	_	_	_	_
29-19	4396-4397	,	_	_	_	_
29-20	4398-4401	and	_	_	_	_
29-21	4402-4405	the	abstract[211]	giv[211]	_	_
29-22	4406-4415	excellent	abstract[211]	giv[211]	_	_
29-23	4416-4424	catalyst	abstract|abstract[211]	giv|giv[211]	coref	39-17[257_0]
29-24	4425-4436	reusability	abstract[211]	giv[211]	_	_
29-25	4437-4438	.	_	_	_	_

#Text=Challenging , in particular with respect to an application in a fixed bed reactor , might be the gel-like consistency of the hydrogel and mass transfer limitations through phase interfaces in general .
30-1	4439-4450	Challenging	_	_	_	_
30-2	4451-4452	,	_	_	_	_
30-3	4453-4455	in	_	_	_	_
30-4	4456-4466	particular	_	_	_	_
30-5	4467-4471	with	_	_	_	_
30-6	4472-4479	respect	abstract[212]	new[212]	_	_
30-7	4480-4482	to	abstract[212]	new[212]	_	_
30-8	4483-4485	an	abstract[212]|abstract[213]	new[212]|giv[213]	_	_
30-9	4486-4497	application	abstract[212]|abstract[213]	new[212]|giv[213]	_	_
30-10	4498-4500	in	abstract[212]|abstract[213]	new[212]|giv[213]	_	_
30-11	4501-4502	a	abstract[212]|abstract[213]|object[215]	new[212]|giv[213]|giv[215]	_	_
30-12	4503-4508	fixed	abstract[212]|abstract[213]|object[215]	new[212]|giv[213]|giv[215]	_	_
30-13	4509-4512	bed	abstract[212]|abstract[213]|place|object[215]	new[212]|giv[213]|giv|giv[215]	_	_
30-14	4513-4520	reactor	abstract[212]|abstract[213]|object[215]	new[212]|giv[213]|giv[215]	_	_
30-15	4521-4522	,	_	_	_	_
30-16	4523-4528	might	_	_	_	_
30-17	4529-4531	be	_	_	_	_
30-18	4532-4535	the	abstract[216]	new[216]	_	_
30-19	4536-4544	gel-like	abstract[216]	new[216]	_	_
30-20	4545-4556	consistency	abstract[216]	new[216]	_	_
30-21	4557-4559	of	abstract[216]	new[216]	_	_
30-22	4560-4563	the	abstract[216]|substance[217]	new[216]|new[217]	_	_
30-23	4564-4572	hydrogel	abstract[216]|substance[217]	new[216]|new[217]	_	_
30-24	4573-4576	and	abstract[216]	new[216]	_	_
30-25	4577-4581	mass	abstract[216]|quantity|abstract[220]	new[216]|giv|new[220]	_	_
30-26	4582-4590	transfer	abstract[216]|abstract|abstract[220]	new[216]|new|new[220]	_	_
30-27	4591-4602	limitations	abstract[216]|abstract[220]	new[216]|new[220]	_	_
30-28	4603-4610	through	abstract[216]|abstract[220]	new[216]|new[220]	_	_
30-29	4611-4616	phase	abstract[216]|abstract[220]|abstract|abstract[222]	new[216]|new[220]|giv|new[222]	_	_
30-30	4617-4627	interfaces	abstract[216]|abstract[220]|abstract[222]	new[216]|new[220]|new[222]	_	_
30-31	4628-4630	in	abstract[216]|abstract[220]|abstract[222]	new[216]|new[220]|new[222]	_	_
30-32	4631-4638	general	abstract[216]|abstract[220]|abstract[222]|person	new[216]|new[220]|new[222]|new	_	_
30-33	4639-4640	.	_	_	_	_

#Text=The absorbent polymer consists of cross-linked polyacrylic acid , which was partially neutralized .
31-1	4641-4644	The	person[224]	giv[224]	coref	32-7[0_224]
31-2	4645-4654	absorbent	person[224]	giv[224]	_	_
31-3	4655-4662	polymer	person[224]	giv[224]	_	_
31-4	4663-4671	consists	_	_	_	_
31-5	4672-4674	of	_	_	_	_
31-6	4675-4687	cross-linked	substance[225]	new[225]	coref	32-22[0_225]
31-7	4688-4699	polyacrylic	substance[225]	new[225]	_	_
31-8	4700-4704	acid	substance[225]	new[225]	_	_
31-9	4705-4706	,	_	_	_	_
31-10	4707-4712	which	_	_	_	_
31-11	4713-4716	was	_	_	_	_
31-12	4717-4726	partially	_	_	_	_
31-13	4727-4738	neutralized	_	_	_	_
31-14	4739-4740	.	_	_	_	_

#Text=Proteins can be embedded in this polymer matrix and can be bound , for example , by ionic interactions of its acid moieties to ionic amino acid residues of the protein ( see
32-1	4741-4749	Proteins	animal	new	_	_
32-2	4750-4753	can	_	_	_	_
32-3	4754-4756	be	_	_	_	_
32-4	4757-4765	embedded	_	_	_	_
32-5	4766-4768	in	_	_	_	_
32-6	4769-4773	this	object[228]	new[228]	ana	32-21[0_228]
32-7	4774-4781	polymer	person|object[228]	giv|new[228]	_	_
32-8	4782-4788	matrix	object[228]	new[228]	_	_
32-9	4789-4792	and	_	_	_	_
32-10	4793-4796	can	_	_	_	_
32-11	4797-4799	be	_	_	_	_
32-12	4800-4805	bound	_	_	_	_
32-13	4806-4807	,	_	_	_	_
32-14	4808-4811	for	_	_	_	_
32-15	4812-4819	example	_	_	_	_
32-16	4820-4821	,	_	_	_	_
32-17	4822-4824	by	_	_	_	_
32-18	4825-4830	ionic	abstract[229]	new[229]	_	_
32-19	4831-4843	interactions	abstract[229]	new[229]	_	_
32-20	4844-4846	of	abstract[229]	new[229]	_	_
32-21	4847-4850	its	abstract[229]|object|substance[232]	new[229]|giv|giv[232]	_	_
32-22	4851-4855	acid	abstract[229]|substance|substance[232]	new[229]|giv|giv[232]	coref	32-27
32-23	4856-4864	moieties	abstract[229]|substance[232]	new[229]|giv[232]	_	_
32-24	4865-4867	to	abstract[229]|substance[232]	new[229]|giv[232]	_	_
32-25	4868-4873	ionic	abstract[229]|substance[232]|substance[235]	new[229]|giv[232]|new[235]	coref	34-9[241_235]
32-26	4874-4879	amino	abstract[229]|substance[232]|object|substance[235]	new[229]|giv[232]|new|new[235]	_	_
32-27	4880-4884	acid	abstract[229]|substance[232]|substance|substance[235]	new[229]|giv[232]|giv|new[235]	_	_
32-28	4885-4893	residues	abstract[229]|substance[232]|substance[235]	new[229]|giv[232]|new[235]	_	_
32-29	4894-4896	of	abstract[229]|substance[232]|substance[235]	new[229]|giv[232]|new[235]	_	_
32-30	4897-4900	the	abstract[229]|substance[232]|substance[235]|substance[236]	new[229]|giv[232]|new[235]|giv[236]	coref	34-10[0_236]
32-31	4901-4908	protein	abstract[229]|substance[232]|substance[235]|substance[236]	new[229]|giv[232]|new[235]|giv[236]	_	_
32-32	4909-4910	(	_	_	_	_
32-33	4911-4914	see	_	_	_	_

#Text=Figure 1
33-1	4915-4921	Figure	object[237]	new[237]	coref	35-1[244_237]
33-2	4922-4923	1	object[237]	new[237]	_	_

#Text=A ) . Also , hydrogen bridges from non-ionic protein residues with superabsorber functionalities (
34-1	4924-4925	A	object[239]	new[239]	_	_
34-2	4926-4927	)	object[239]	new[239]	_	_
34-3	4928-4929	.	object[239]	new[239]	_	_
34-4	4930-4934	Also	object[239]	new[239]	_	_
34-5	4935-4936	,	object[239]	new[239]	_	_
34-6	4937-4945	hydrogen	substance|object[239]	new|new[239]	_	_
34-7	4946-4953	bridges	object[239]	new[239]	_	_
34-8	4954-4958	from	object[239]	new[239]	_	_
34-9	4959-4968	non-ionic	object[239]|substance[241]	new[239]|giv[241]	coref	36-8[249_241]
34-10	4969-4976	protein	object[239]|substance|substance[241]	new[239]|giv|giv[241]	_	_
34-11	4977-4985	residues	object[239]|substance[241]	new[239]|giv[241]	_	_
34-12	4986-4990	with	object[239]|substance[241]	new[239]|giv[241]	_	_
34-13	4991-5004	superabsorber	object[239]|substance[241]|object|abstract[243]	new[239]|giv[241]|giv|new[243]	_	_
34-14	5005-5020	functionalities	object[239]|substance[241]|abstract[243]	new[239]|giv[241]|new[243]	_	_
34-15	5021-5022	(	_	_	_	_

#Text=Figure 1
35-1	5023-5029	Figure	object[244]	giv[244]	coref	37-1[250_244]
35-2	5030-5031	1	object[244]	giv[244]	_	_

#Text=B ) or entrapment of enzyme in superabsorber-bound water residues (
36-1	5032-5033	B	person	new	_	_
36-2	5034-5035	)	_	_	_	_
36-3	5036-5038	or	_	_	_	_
36-4	5039-5049	entrapment	abstract[246]	new[246]	_	_
36-5	5050-5052	of	abstract[246]	new[246]	_	_
36-6	5053-5059	enzyme	abstract[246]|substance[247]	new[246]|giv[247]	_	_
36-7	5060-5062	in	abstract[246]|substance[247]	new[246]|giv[247]	_	_
36-8	5063-5082	superabsorber-bound	abstract[246]|substance[247]|substance[249]	new[246]|giv[247]|giv[249]	_	_
36-9	5083-5088	water	abstract[246]|substance[247]|substance|substance[249]	new[246]|giv[247]|new|giv[249]	_	_
36-10	5089-5097	residues	abstract[246]|substance[247]|substance[249]	new[246]|giv[247]|giv[249]	_	_
36-11	5098-5099	(	_	_	_	_

#Text=Figure 1
37-1	5100-5106	Figure	object[250]	giv[250]	_	_
37-2	5107-5108	1	object[250]	giv[250]	_	_

#Text=C ) can be a possible mode of interaction .
38-1	5109-5110	C	abstract	new	coref	38-5[252_0]
38-2	5111-5112	)	_	_	_	_
38-3	5113-5116	can	_	_	_	_
38-4	5117-5119	be	_	_	_	_
38-5	5120-5121	a	abstract[252]	giv[252]	_	_
38-6	5122-5130	possible	abstract[252]	giv[252]	_	_
38-7	5131-5135	mode	abstract[252]	giv[252]	_	_
38-8	5136-5138	of	abstract[252]	giv[252]	_	_
38-9	5139-5150	interaction	abstract[252]|abstract	giv[252]|new	_	_
38-10	5151-5152	.	_	_	_	_

#Text=An ( R )-enantioselective ADH from Lactobacillus brevis ( LB-ADH ) has been shown to be a versatile catalyst for the reduction of a variety of ketones , ranging from aliphatic ketones to benzylic or propargylic ketones .
39-1	5153-5155	An	person[254]	new[254]	_	_
39-2	5156-5157	(	person[254]	new[254]	_	_
39-3	5158-5159	R	person[254]	new[254]	_	_
39-4	5160-5178	)-enantioselective	person[254]	new[254]	_	_
39-5	5179-5182	ADH	abstract[255]	giv[255]	coref	43-8[276_255]
39-6	5183-5187	from	abstract[255]	giv[255]	_	_
39-7	5188-5201	Lactobacillus	abstract[255]	giv[255]	_	_
39-8	5202-5208	brevis	abstract[255]	giv[255]	_	_
39-9	5209-5210	(	_	_	_	_
39-10	5211-5217	LB-ADH	substance	giv	_	_
39-11	5218-5219	)	_	_	_	_
39-12	5220-5223	has	_	_	_	_
39-13	5224-5228	been	_	_	_	_
39-14	5229-5234	shown	_	_	_	_
39-15	5235-5237	to	_	_	_	_
39-16	5238-5240	be	_	_	_	_
39-17	5241-5242	a	object[257]	giv[257]	coref	40-11[264_257]
39-18	5243-5252	versatile	object[257]	giv[257]	_	_
39-19	5253-5261	catalyst	object[257]	giv[257]	_	_
39-20	5262-5265	for	object[257]	giv[257]	_	_
39-21	5266-5269	the	object[257]|abstract[258]	giv[257]|new[258]	_	_
39-22	5270-5279	reduction	object[257]|abstract[258]	giv[257]|new[258]	_	_
39-23	5280-5282	of	object[257]|abstract[258]	giv[257]|new[258]	_	_
39-24	5283-5284	a	object[257]|abstract[258]|abstract[259]	giv[257]|new[258]|new[259]	ana	40-1[0_259]
39-25	5285-5292	variety	object[257]|abstract[258]|abstract[259]	giv[257]|new[258]|new[259]	_	_
39-26	5293-5295	of	object[257]|abstract[258]|abstract[259]	giv[257]|new[258]|new[259]	_	_
39-27	5296-5303	ketones	object[257]|abstract[258]|abstract[259]|substance	giv[257]|new[258]|new[259]|new	coref	39-31[261_0]
39-28	5304-5305	,	_	_	_	_
39-29	5306-5313	ranging	_	_	_	_
39-30	5314-5318	from	_	_	_	_
39-31	5319-5328	aliphatic	substance[261]	giv[261]	_	_
39-32	5329-5336	ketones	substance[261]	giv[261]	_	_
39-33	5337-5339	to	substance[261]	giv[261]	_	_
39-34	5340-5348	benzylic	substance[261]|substance	giv[261]|new	_	_
39-35	5349-5351	or	substance[261]	giv[261]	_	_
39-36	5352-5363	propargylic	substance[261]	giv[261]	_	_
39-37	5364-5371	ketones	substance[261]	giv[261]	_	_
39-38	5372-5373	.	_	_	_	_

#Text=It can be used as an isolated enzyme or as a whole-cell catalyst .
40-1	5374-5376	It	abstract	giv	ana	41-4
40-2	5377-5380	can	_	_	_	_
40-3	5381-5383	be	_	_	_	_
40-4	5384-5388	used	_	_	_	_
40-5	5389-5391	as	_	_	_	_
40-6	5392-5394	an	_	_	_	_
40-7	5395-5403	isolated	_	_	_	_
40-8	5404-5410	enzyme	_	_	_	_
40-9	5411-5413	or	_	_	_	_
40-10	5414-5416	as	_	_	_	_
40-11	5417-5418	a	abstract[264]	giv[264]	_	_
40-12	5419-5429	whole-cell	abstract[264]	giv[264]	_	_
40-13	5430-5438	catalyst	abstract[264]	giv[264]	_	_
40-14	5439-5440	.	_	_	_	_

#Text=In particular , its tolerance towards organic solvents is outstanding .
41-1	5441-5443	In	_	_	_	_
41-2	5444-5454	particular	_	_	_	_
41-3	5455-5456	,	_	_	_	_
41-4	5457-5460	its	abstract|abstract[266]	giv|new[266]	_	_
41-5	5461-5470	tolerance	abstract[266]	new[266]	_	_
41-6	5471-5478	towards	abstract[266]	new[266]	_	_
41-7	5479-5486	organic	abstract[266]|substance[267]	new[266]|giv[267]	_	_
41-8	5487-5495	solvents	abstract[266]|substance[267]	new[266]|giv[267]	_	_
41-9	5496-5498	is	_	_	_	_
41-10	5499-5510	outstanding	_	_	_	_
41-11	5511-5512	.	_	_	_	_

#Text=The stability depends on several factors , such as the nature of the buffer or solvent additives .
42-1	5513-5516	The	abstract[268]	new[268]	_	_
42-2	5517-5526	stability	abstract[268]	new[268]	_	_
42-3	5527-5534	depends	_	_	_	_
42-4	5535-5537	on	_	_	_	_
42-5	5538-5545	several	abstract[269]	new[269]	_	_
42-6	5546-5553	factors	abstract[269]	new[269]	_	_
42-7	5554-5555	,	abstract[269]	new[269]	_	_
42-8	5556-5560	such	abstract[269]	new[269]	_	_
42-9	5561-5563	as	abstract[269]	new[269]	_	_
42-10	5564-5567	the	abstract[269]|abstract[270]	new[269]|new[270]	_	_
42-11	5568-5574	nature	abstract[269]|abstract[270]	new[269]|new[270]	_	_
42-12	5575-5577	of	abstract[269]|abstract[270]	new[269]|new[270]	_	_
42-13	5578-5581	the	abstract[269]|abstract[270]|substance[271]	new[269]|new[270]|new[271]	_	_
42-14	5582-5588	buffer	abstract[269]|abstract[270]|substance[271]	new[269]|new[270]|new[271]	_	_
42-15	5589-5591	or	abstract[269]|abstract[270]	new[269]|new[270]	_	_
42-16	5592-5599	solvent	abstract[269]|abstract[270]|abstract|substance[273]	new[269]|new[270]|new|new[273]	_	_
42-17	5600-5609	additives	abstract[269]|abstract[270]|substance[273]	new[269]|new[270]|new[273]	_	_
42-18	5610-5611	.	_	_	_	_

#Text=In this contribution , the application of a superabsorber-immobilized ADH from L. brevis for an enzymatic reduction of acetophenone ( 1 ) in a flow process is described .
43-1	5612-5614	In	_	_	_	_
43-2	5615-5619	this	abstract[274]	new[274]	_	_
43-3	5620-5632	contribution	abstract[274]	new[274]	_	_
43-4	5633-5634	,	_	_	_	_
43-5	5635-5638	the	abstract[275]	new[275]	_	_
43-6	5639-5650	application	abstract[275]	new[275]	_	_
43-7	5651-5653	of	abstract[275]	new[275]	_	_
43-8	5654-5655	a	abstract[275]|abstract[276]	new[275]|giv[276]	_	_
43-9	5656-5681	superabsorber-immobilized	abstract[275]|abstract[276]	new[275]|giv[276]	_	_
43-10	5682-5685	ADH	abstract[275]|abstract[276]	new[275]|giv[276]	_	_
43-11	5686-5690	from	abstract[275]	new[275]	_	_
43-12	5691-5693	L.	abstract[275]	new[275]	_	_
43-13	5694-5700	brevis	abstract[275]	new[275]	_	_
43-14	5701-5704	for	abstract[275]	new[275]	_	_
43-15	5705-5707	an	abstract[275]|abstract[277]	new[275]|new[277]	_	_
43-16	5708-5717	enzymatic	abstract[275]|abstract[277]	new[275]|new[277]	_	_
43-17	5718-5727	reduction	abstract[275]|abstract[277]	new[275]|new[277]	_	_
43-18	5728-5730	of	abstract[275]|abstract[277]	new[275]|new[277]	_	_
43-19	5731-5743	acetophenone	abstract[275]|abstract[277]|substance[278]	new[275]|new[277]|new[278]	_	_
43-20	5744-5745	(	abstract[275]|abstract[277]|substance[278]	new[275]|new[277]|new[278]	_	_
43-21	5746-5747	1	abstract[275]|abstract[277]|substance[278]	new[275]|new[277]|new[278]	_	_
43-22	5748-5749	)	abstract[275]|abstract[277]|substance[278]	new[275]|new[277]|new[278]	_	_
43-23	5750-5752	in	_	_	_	_
43-24	5753-5754	a	abstract[280]	new[280]	_	_
43-25	5755-5759	flow	abstract|abstract[280]	new|new[280]	_	_
43-26	5760-5767	process	abstract[280]	new[280]	_	_
43-27	5768-5770	is	_	_	_	_
43-28	5771-5780	described	_	_	_	_
43-29	5781-5782	.	_	_	_	_
